AUSTIN, Texas, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the fourth quarter and year ended December 31, 2022, and provided an overview of recent business highlights.
“During 2022, we made significant progress in our co-lead radiotherapeutic programs for recurrent glioblastoma (GBM) and LM. Furthermore, even during a turbulent time in the U.S. capital markets, we reached a new level of balance sheet stability to support our exciting and potentially game-changing targeted radiotherapeutic drug candidates,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. “In 2023, we intend to build on the success of 2022 to simultaneously advance our active programs in GBM and LM and also broaden and diversify our drug development pipeline.”
2022 AND 2023 HIGHLIGHTS AND MILESTONE ACHIEVEMENTS
FULL YEAR 2022 FINANCIAL RESULTS
UPCOMING EVENTS AND MILESTONES
During 2023, the Company expects to accomplish the following key business objectives:
FOURTH QUARTER AND FULL YEAR 2022 RESULTS CONFERENCE CALL
The Company will hold a conference call and live audio webcast at 5:00 p.m. Eastern Time today to discuss its financial results and provide a general business update.
A live webcast will be available at ir.plustherapeutics.com/events.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company’s website under the 'For Investor' section. The webcast will be available on the Company’s website for 90 days following the live call.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a robust supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “expects”, “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; statements with respect to the Company’s capital resources; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
PLUS THERAPEUTICS, INC.
BALANCE SHEETS
(in thousands, except share and par value data)
| As of December 31, | ||||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 18,120 | $ | 18,400 | ||||
| Other current assets | 3,697 | 1,324 | ||||||
| Total current assets | 21,817 | 19,724 | ||||||
| Property and equipment, net | 1,324 | 1,477 | ||||||
| Operating lease right-use-of assets | 248 | 341 | ||||||
| Goodwill | 372 | 372 | ||||||
| Intangible assets, net | 94 | 51 | ||||||
| Other assets | 12 | 16 | ||||||
| Total assets | $ | 23,867 | $ | 21,981 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 10,134 | $ | 4,151 | ||||
| Operating lease liability | 110 | 111 | ||||||
| Term loan obligation, current | 1,608 | 1,608 | ||||||
| Total current liabilities | 11,852 | 5,870 | ||||||
| Noncurrent operating lease liability | 141 | 269 | ||||||
| Term loan obligation | 3,786 | 5,005 | ||||||
| Deferred grant liability | 1,643 | — | ||||||
| Warrant liability | — | 1 | ||||||
| Total liabilities | 17,422 | 11,145 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding as of December 31, 2022 and 2021 | — | — | ||||||
| Common stock, $0.001 par value; 100,000,000 shares authorized; 33,601,373 and 15,510,025 shares issued and outstanding as of December 31, 2022 and 2021, respectively | 34 | 16 | ||||||
| Additional paid-in capital | 473,596 | 457,730 | ||||||
| Accumulated deficit | (467,185 | ) | (446,910 | ) | ||||
| Total stockholders’ equity | 6,445 | 10,836 | ||||||
| Total liabilities and stockholders’ equity | $ | 23,867 | $ | 21,981 | ||||
PLUS THERAPEUTICS, INC.
STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
| For the Years Ended December 31, | ||||||||
| 2022 | 2021 | |||||||
| Grant revenue | $ | 224 | $ | — | ||||
| Operating expenses: | ||||||||
| Research and development | 9,698 | 5,323 | ||||||
| In process research and development acquired | — | 250 | ||||||
| General and administrative | 10,238 | 6,853 | ||||||
| Loss on disposal of property and equipment | — | 66 | ||||||
| Total operating expenses | 19,936 | 12,492 | ||||||
| Operating loss | (19,712 | ) | (12,492 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 147 | 19 | ||||||
| Interest expense | (711 | ) | (932 | ) | ||||
| Change in fair value of liability instruments | 1 | 6 | ||||||
| Total other expense | (563 | ) | (907 | ) | ||||
| Net loss | $ | (20,275 | ) | $ | (13,399 | ) | ||
| Net loss per share, basic and diluted | $ | (0.77 | ) | $ | (1.11 | ) | ||
| Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders | 26,255,256 | 12,089,186 | ||||||
PLUS THERAPEUTICS, INC.
STATEMENTS OF CASH FLOWS
(in thousands)
| For the Years Ended December 31, | ||||||||
| 2022 | 2021 | |||||||
| Cash flows used in operating activities: | ||||||||
| Net loss | $ | (20,275 | ) | $ | (13,399 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 619 | 395 | ||||||
| Amortization of deferred financing costs and debt discount | 389 | 546 | ||||||
| In process research and development acquired | — | 250 | ||||||
| Change in fair value of liability instruments | (1 | ) | (6 | ) | ||||
| Loss on disposal of property and equipment | — | 66 | ||||||
| Share-based compensation expense | 606 | 606 | ||||||
| Amortization of operating lease right-of-use assets | 93 | 24 | ||||||
| Increases (decreases) in cash caused by changes in operating assets and liabilities: | ||||||||
| Other current assets | (2,369 | ) | (496 | ) | ||||
| Accounts payable and accrued expenses | 6,452 | 1,734 | ||||||
| Change in operating lease liabilities | (129 | ) | — | |||||
| Other long-term liabilities | 1,643 | — | ||||||
| Net cash used in operating activities | (12,972 | ) | (10,280 | ) | ||||
| Cash flows used in investing activities: | ||||||||
| Purchases of property and equipment and intangible assets | (509 | ) | (144 | ) | ||||
| In process research and development acquired | (250 | ) | — | |||||
| Proceeds from sale of property and equipment | — | 62 | ||||||
| Net cash used in investing activities | (759 | ) | (82 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Principal payments of long-term obligations | (1,608 | ) | (268 | ) | ||||
| Payment of finance lease liability | — | (8 | ) | |||||
| Proceeds from exercise of warrants | — | 2,017 | ||||||
| Proceeds from sale of common stock | 15,059 | 18,675 | ||||||
| Net cash provided by financing activities | 13,451 | 20,416 | ||||||
| Net increase (decrease) in cash and cash equivalents | (280 | ) | 10,054 | |||||
| Cash and cash equivalents at beginning of period | 18,400 | 8,346 | ||||||
| Cash and cash equivalents at end of period | $ | 18,120 | $ | 18,400 | ||||
| Supplemental disclosure of cash flows information: | ||||||||
| Cash paid during period for: | ||||||||
| Interest | $ | 327 | $ | 388 | ||||
| Supplemental schedule of non-cash investing and financing activities: | ||||||||
| Unpaid offering cost | $ | — | $ | 219 | ||||
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.20 |
| Daily Change: | -0.05 -3.63 |
| Daily Volume: | 15,240 |
| Market Cap: | US$7.050M |
November 14, 2024 November 06, 2024 October 29, 2024 October 01, 2024 September 18, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
